Cellectar Biosciences Inc. (CLRB), a late-stage clinical biopharmaceutical company, on Monday released positive results from the Phase 2b CLOVER WaM trial for Iopofosine I 131 in treating patients with relapsed/refractory Waldenstrom macroglobulinemia, including those immediately post-BTKi therapy. Data were presented at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO).
Waldenstrom macroglobulinemia (WM), is a type of indolent B-cell non-Hodgkin lymphoma characterized by the accumulation of lymphoplasmacytic cells and the overproduction of monoclonal immunoglobulin M (IgM). The cancer is typically treated with Bruton Tyrosine Kinase inhibitor (BTKi) therapy, yet there are no FDA-approved treatments for patients showing rapid disease progression after discontinuing the therapy.
Iopofosine I 131 is a phospholipid-drug conjugate (PDC) designed for the targeted delivery of the radioisotope iodine-131 to various tumor types. The FDA has granted the drug a Breakthrough designation, six Orphan Drug, four Rare Pediatric Drug designations, and two Fast Track Designations for various cancer indications, and the EMA has granted it a PRIority MEdicines (PRIME) designation.
The Phase 2b CLOVER WaM trial evaluated Iopofosine I 131 in patients of Waldenstrom macroglobulinemia by administering 15 mCi/m2 on days 1 and 15 of a 57-day cycle. Eligible patients had received at least two prior therapies and has symptomatic disease.
Significant efficacy results were observed, including a 100% clinical benefit rate (CBR), an 87.5% objective response rate (ORR), and a 79.2% rate of major response, partial response, or better. The median duration of response was 16 months, and 20% of participants showed a duration of response of 30 months or more.
Treatment was well-tolerated, with cytopenias as the only Grade 3 or greater adverse event reported.
The company plans to initiate a Phase 3 pivotal trial in the fourth quarter of 2026.
Company executives emphasized the significance of these results. COO Jarrod Longcor noted the strong efficacy in patients post-BTKi therapy while CEO James Caruso highlighted the potential path toward accelerated approval.
Additionally, Iopofosine I 131 is being advanced in a Phase 1 trial for treating high-grade pediatric gliomas and may receive a Pediatric Review Voucher upon FDA approval. The drug is also being explored for the treatment of relapsed/refractory multiple myeloma, and central nervous system lymphoma.
Cellectar's pipeline also includes CLR 125, a targeted radiotherapy for solid tumors, and CLR 225, a next-generation PDC platform.
CLRB closed Monday at $2.97, down 5.41%. In the pre-market, shares are trading at $3.09, up 3.96%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.